Logotype for Y-mAbs Therapeutics Inc

Y-mAbs Therapeutics (YMAB) investor relations material

Y-mAbs Therapeutics Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Y-mAbs Therapeutics Inc
Q2 2025 earnings summary8 Aug, 2025

Executive summary

  • Entered into a definitive merger agreement with Perseus BidCo US, Inc. and SERB Pharmaceuticals for a cash tender offer at $8.60 per share, with the company to become a wholly owned subsidiary upon completion; deal valued at $412 million and expected to close by Q4 2025.

  • DANYELZA remains the only FDA-approved product, with ongoing clinical trials and expansion into new indications and geographies.

  • Business realignment in January 2025 led to a 12% workforce reduction, operational restructuring into two segments, and reduced personnel and compensation costs.

  • Cash and cash equivalents stood at $62.3 million as of June 30, 2025.

Financial highlights

  • Q2 2025 revenues were $19.5 million, down 14% year-over-year but exceeding guidance, mainly due to lower DANYELZA sales in the US and ex-US markets.

  • Net loss for Q2 2025 was $3.2 million, or ($0.07) per share, improved from $9.2 million or ($0.21) per share in Q2 2024.

  • Gross margin for Q2 2025 was 86%.

  • Operating expenses declined due to lower R&D and SG&A costs, including the absence of prior year litigation settlements.

  • Interest and other income rose to $2.3 million, mainly from foreign currency gains.

Outlook and guidance

  • Cash position projected to support operations as currently planned into 2028, assuming no merger completion.

  • Ongoing clinical trials for DANYELZA and SADA PRIT platform, with key studies expected to complete enrollment or report results by 2028.

  • Manufacturing transition for DANYELZA to Italy in 2026 may temporarily increase costs and inventory levels.

  • Transaction with SERB expected to close by Q4 2025, pending tender offer and regulatory approvals.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Y-mAbs Therapeutics earnings date

Logotype for Y-mAbs Therapeutics Inc
Q3 20257 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Y-mAbs Therapeutics earnings date

Logotype for Y-mAbs Therapeutics Inc
Q3 20257 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Y-mAbs Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of antibody-based therapies for the treatment of cancer. The company specializes in creating monoclonal antibody treatments that target tumors in pediatric and adult patients. Y-mAbs leverages its expertise in immunotherapies to advance a pipeline of innovative treatments designed to improve survival rates and patient outcomes in oncology. Its focus is primarily on addressing rare and difficult-to-treat cancers. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage